CDC Recommends Other COVID-19 Vaccines Be Preferred Over Janssen/J&J

Based on concerns about the increased incidence of thrombosis with thrombocytopenia (TTS) in people who received the Janssen/Johnson & Johnson (J&J) COVID-19 vaccine, an advisory committee of the US Centers for Disease Control and Prevention (CDC) recommended that COVID-19 vaccines other than Johnson & Johnson’s be preferred. The CDC states that the US TTS case reporting rate following Janssen COVID-19 vaccination is higher than previously presented.

The TTS risk is estimated to occur in 1 in 100,000 people who received the vaccine. The FDA issued an updated fact sheet for the Janssen/J&J vaccine reflecting concern about the TTS risk linked to the vaccine. The Janssen/J&J COVID-19 vaccine should not be administered to individuals with a history of TTS following receipt of this vaccine or any other adenovirus-vectored COVID-19 vaccines, according to a newly revised FDA vaccine fact sheet.

Reports from the Vaccine Adverse Events Reporting System (VAERS) show that the onset of symptoms occurred approximately 1 to 2 weeks after administration of the Janssen COVID-19 vaccine. Cases were reported in both males and females, with approximately 15% of cases being fatal. The highest rate was reported in females 30 to 49 years of age.

Join our email list

Get new course alerts, newsletters and more delivered directly to your inbox

By providing my personal information, including phone number, I consent to (1) receive email messages with information and offers, autodialed calls, texts, and prerecorded messages from FHEA, including current and possible future services, customer service and billing; and (2) FHEA’s Privacy Policy and Terms and Conditions. I understand that my consent is not required to purchase, and that cancellation of purchase does not automatically revoke this consent.